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Bone morphometryFibroblast growth factor 23 (FGF23), a bone-derived hormone, participates in the hormonal bone–parathyroid–
kidney axis, which is modulated by PTH, 1,25-dihydroxyvitamin D, plasma phosphate (Pi), and diet. Inappropri-
ately high serum FGF23, seen in certain genetic and acquired disorders, results in urinary phosphate wasting and
impaired bonemineralization. This study investigated the impact of FGF23 gene variation on phosphate homeo-
stasis and bone health. The study included 183 children and adolescents (110 girls) aged 7–19 years (median
13.2 years). Urine and blood parameters of calcium and phosphate homeostasis were analyzed. Bone character-
istics were quantiﬁed by DXA and peripheral quantitative computed tomography (pQCT). Genetic FGF23
variation was assessed by direct sequencing of coding exons and ﬂanking intronic regions. Nine FGF23 polymor-
phismswere detected; three of themwere common: rs3832879 (c.212-37insC), rs7955866 (c.716CNT, p.T239M)
and rs11063112 (c.2185ANT). Four different haplotypes and six different diplotypeswere observed among these
three polymorphisms. The variations in FGF23 signiﬁcantly associatedwith plasma PTH and urinary Pi excretion,
even after adjusting for relevant covariates. FGF23 variations independently associated with total hip BMD
Z-score, but not with other bone outcomes. In instrument analysis, genetic variance in FGF23 was considered a
weak instrument as it only induced small variations in circulating FGF23, PTH and Pi concentrations (F statistic
less than 10). The observed associations between FGF23 variations and circulating PTH, and Pi excretion and
total hip BMD Z-scores suggest that FGF23 polymorphisms may play a role in mineral homeostasis and bone
metabolism.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Fibroblast growth factor (FGF) 23 is a member of the FGF family of
polypeptides, which regulates diverse functions in metabolism and
development. FGF23 is a hormone mainly produced by osteoblasts
and osteocytes and regulates phosphate homeostasis and vitamin D
metabolism via a speciﬁc FGF receptor-α-klotho-complex in tubular
kidney cells, thereby participating in the hormonal bone–kidney, the Yrjö Jahnsson Foundation,
780 and #277843), the Helsinki
Juselius Foundation and the
dish Research Council (#2013-
tics, Biomedicum Helsinki, P.O.
d. Fax: +358 9 191 25073.
nen).
. This is an open access article underaxis [1–3]. FGF23 acts to decrease urinary phosphate reuptake by
downregulating a sodium-dependent phosphate co-transporter, by
inhibiting the CYP27B1 enzyme responsible for 1-hydroxylation of 25-
hydroxyvitamin D (25(OH)D), and by inducing 1,25-dihydroxyvitamin
D (1,25(OH)2D) inactivation [4,5]. Phosphate is an essential mineral for
skeletal mineralization, cellular energy maintenance and for buffering
blood pH levels, but high plasma phosphate levels may be a risk for
soft tissue calciﬁcation [6]. Phosphate is mainly bound to hydroxyapa-
tite in bone and to intracellular components, and only approximately
1% circulates in the blood. The circulating phosphate concentration is
regulated by FGF23, 1,25(OH)2D and PTH levels [1].
The signiﬁcance of FGF23 in the pathogenesis of hypophosphatemic
disorders was unveiled when FGF23 was discovered as the causative
gene behind autosomal dominant hypophosphatemic rickets (ADHR),
and tumor-induced phosphate wasting was associated with increased
FGF23 synthesis. High FGF23 in these diseases leads to excessive urinarythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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[5,7,8]. FGF23 is normally inactivated by enzymatic cleavage, but
FGF23 mutations in ADHR render the protein's cleavage site resistant
to degradation, thereby elevating circulating FGF23 [9,10]. In tumor-
induced osteomalacia the tumor itself produces excess FGF23 and
hypophosphatemia can be reversed by tumor removal [5].
A functional allelic variant rs7955866 (c.716CNT, p.T239M) in
FGF23 has recently been linked to renal phosphate leak in calcium
nephrolithiasis [11]. FGF23716Tsubjects had lower plasma phosphate
(P-Pi) and reduced renal tubular phosphate reabsorption compared
with FGF23716C subjects. In addition, the p.T239M change increased
FGF23 secretion and induced a higher activation of the FGF recep-
tor/ERK pathway compared to FGF23239T [11].
The impact of FGF23 gene variation on healthy populations has
received little attention in research. The aim of this study was to
explore genetic variations in the FGF23 gene and to study whether
the gene variants associate with biochemical parameters of
phosphate and calcium homeostasis and with bone outcomes
(measured with DXA and pQCT) in healthy children and
adolescents.
Methods
Study population
A total of 183 children and adolescents, 110 girls (median age 13.3,
range 7.4–18.8 years) and 73 boys (median age 12.6, range 7.7–
18.1 years), were included in this school-based cross-sectional study
in the capital region of Helsinki, in southern Finland (latitude 61°).
The primary aim of the original study was to evaluate skeletal
health in relation to vitamin D status during childhood and puberty;
the secondary aim was to explore FGF23 gene variation and its role
in bone health and mineral metabolism. The original cohort includ-
ed 195 subjects [12] who were recruited from one primary and
one secondary school; DNA was obtained for 183 of these subjects
(94% of the original cohort), who were included in the present study.
More than 95% of the subjects were Caucasian. All participants and
their parents gave informed written consent before entering the
study. The study was approved by the Research Ethics Committee of
Helsinki University Hospital and performed according to the Declara-
tion of Helsinki.
Background and clinical data
The subjects completed a questionnaire on overall health, medical
and fracture history, medications, age at menarche, use of supplements
and details about their physical activity. If necessary, additional
information was obtained by interview. Dietary vitamin D and calcium
intakes during the previous month were estimated using a food fre-
quency questionnaire (covering over 70 foods), which has been validat-
ed against S-25(OH)D and 3-day food records [13–15]. The calculations
of the food nutrient contentswere performed using the FinnishNational
Food Composition Database (Fineli®, version 2001, National Institute
for Health and Welfare). The recorded physical activity data included
regular every-day activities (e.g. walking to school), activity at school,
and both guided and unguided leisure-time activities during two pre-
ceding years. The duration, frequency and intensity of activity sessions
were evaluated. A total physical activity score was obtained by adding
the indices and intensity, as described in detail previously [12]. Heights
andweightsweremeasured and comparedwith Finnish normative data
[16,17]. In the absence of Finnish normative data, body mass index
Z-scores were calculated according to WHO (http://www.who.int).
Pubertal development was scored either pre-, mid- or postpubertal
based on serum hormone concentrations by a pediatric endocrinologist
(OM).Biochemistry
Blood samples and second void urine were collected at 8–10 am
after an overnight fast. All samples were collected between November
and March (wintertime). Plasma calcium (Ca), phosphate (Pi), alkaline
phosphatase (ALP) and urinary concentrations of Ca, Pi and creatinine
were measured using standard methods. Reference ranges for plasma
ALPwere age-and sex-dependent and themeasured values were trans-
formed into Z-scores using normal values to allow for cross-sectional
comparison. S-25(OH)D was assayed with high-performance liquid
chromatography (HPLC, evaluated Vitamin D External Quality Assess-
ment Scheme, DEQAS), and plasma fasting parathyroid hormone
(PTH) by an immunoluminometric method. Total serum intact FGF23
was analyzed by ELISA assay (FGF23 Kit, Kainos laboratories INC.,
Tokyo, Japan). Bone turnover markers N-terminal propeptide of type
I procollagen (PINP) and C-terminal telopeptide of type I collagen
(ICTP), reﬂecting bone formation and resorption, were measured
from serum by radioimmunoassay (UniQ, Orion Diagnostica, Espoo,
Finland) and results were interpreted in comparison to in-house
age-speciﬁc reference values and transformed into Z-scores. All blood
and urine measurements were analyzed at the Central Laboratory of
Helsinki University Central Hospital.
Bone density and body composition measurements
BMD, bone mineral content (BMC) and bone area (BA) were
measured with dual X-ray absorptiometry (DXA, Hologic Discovery A,
pediatric software version 12.4, Bedford, MA, USA) for lumbar spine
(LS) (L1–L4), total hip and whole body (WB). All measured values
were transformed into Z-scores using equipment-speciﬁc age- and
sex-adjusted reference data for US Caucasian children; all subjects
were of normal height. Body composition was analyzed with DXA to
distinguish between lean and fatmass. Calibration of themeasurements
was performed with a spine phantom; inter-CV% for the phantom BMC,
BA, and BMD was 0.35%, 0.21%, and 0.41%, respectively. The reproduc-
ibility of the DXA measurement for bone, fat, and lean mass is 1.2%,
1.9% and 0.7%, respectively, in children between 10 and 18 years of
age [18]. Age- and gender-speciﬁc reference values were utilized to
derive Z-scores for fat percentage [19,20].
Volumetric BMD and bone geometry weremeasured from nondom-
inant radius with pQCT (XCT-2000; Stratec, Pforzheim,Germany,
software version 5.50) as described previously [21,22]. The scans were
analyzed using contour mode 2 (45%) and peel mode 1 to assess total
bone (TB) and trabecular bone (Trab) parameters at the 4% site. At the
66% site, cortical bone (Cort) was detected with separation mode 1
and a threshold of 710 mg/cm3. In addition, we calculated age- and
sex-speciﬁc Z-scores for total cross-sectional area (CSA), bone mineral
content (BMC), Cort mineral density, TB mineral density and stress
and strain index (SSI) using the published Cole's formula, which is
based on mostly Caucasian reference data [23,24].
Genetic analysis
Patient DNA was extracted from peripheral blood by standard
methods. Primers for FGF23 (hg18/uc001qmq1) were designed with
Primer3 v.0.4.0 (http://frodo.wi.mit.edu/primer3/) for all three exons,
UTRs and a minimum of 30 bases of ﬂanking introns. Due to the length
of exon 3 and the 3′UTR, this segmentwas sequencedwith four overlap-
ping primer pairs. PCR ampliﬁcation was performed with AmpliTaq
Gold (Applied Biosystems, Foster City, CA, USA). The DNA fragments
were then visualized with ethidium bromide on a 1.2% agarose gel, pu-
riﬁed with ExoSAP (USB, Cleveland, OH, USA) and labeled with BigDye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). After se-
quencing with an ABI3730 sequencer (Applied Biosystems), chromato-
grams were analyzed with Sequencher v4.7 (Gene Codes Corporation,
Ann Arbor, MI, USA). Primer sequences and detailed PCR protocols are
Table 1
Clinical, biochemical and bone densitometry ﬁndings in the study subjects. Data are given
as medians and ranges.
Girls (N = 110) Boys (N = 73) p-
Value
Age 13.3 (7–19) 12.7 (8–17) 0.035
Pubertal stage 0.012
Prepubertal 22 38
Pubertal 34 12
Postpubertal 53 23
Height (cm) 160 (122.5–178.2) 151.4 (118.5–
199.9)
0.131
Fat % 28.6 (13.6–49.8) 22.8 (9.5–43.7) 0.044
Fat % (Z-score) −0.5
(−2.76–+2.82)
−0.4
(−2.38–+3.92)
0.185
Calcium intake (mg/day) 1407 (477–3618) 1506 (743–2976) 0.063
Vitamin D intake (μg/d) 9.1 (2–27) 10 (3–24) 0.918
Physical activity score 18 (6.5–27) 19 (10–26) 0.545
S-25(OH)D (nmol/L) 41 (18–82) 45 (17–77) 0.097
P-PTH (ng/L) 39.5 (14–135) 38 (3–136) 0.236
S-FGF23 (ng/L) 36 (7–101) 37 (10–105) 0.658
P-Ca (mmol/L) 2.32 (2.1–2.6) 2.32 (2.2–2.6) 0.605
P-Pi (mmol/L) 1.35 (1–1.82) 1.46 (0.83–2.11) 0.203
U-Ca/U-Crea (mmol/L/
mmol/L)
0.14 (0.03–0.68) 0.15 (0.02–0.88) 0.223
U-Pi/U-Crea (mmol/L/mmol/
L)
0.15 (0.05–4.98) 1.72 (0.4–19.7) 0.375
DXA ﬁndings
Lumbar spine BMD (Z-
score)
−0.1 (−2.2–+2.7) +0.1 (−1.3–+2.6) 0.182
Total hip BMD (Z-score) +0.2 (−1.9–2.5) +0.1 (−1.6–1.9) 0.052
Whole Body BMD (Z-
score)
+0.05
(−1.8–+2.4)
+0.0 (−1.5–+2.4) 0.138
pQCT ﬁndings
BMC 4% (Z-score) −0.22
(−3.0–+2.5)
−0.2 (−2.7–+2.1) 0.531
Trabecular vBMD 4% (Z-
score)
−0.1 (−2.7–+2.1) −0.2 8
(−2.2–+2.7)
0.735
Total vBMD 4% (Z-score) −0.3 (−2.7–+2.8) +0.7 (−2.9–+3.6) 0.672
SSI 66% (Z-score) −0.35 (−5.4– 2.1) −0.01
(−2.4–+3.0)
0.518
BMC 66% (Z-score) −0.1 (−2.6–+2.3) +0.4 (−3.0–+3.2) 0.465
Cortical vBMD 66% (Z-
score)
−0.34
(−3.0–+1.9)
−0.7 (−4.0–+1.6) 0.462
Muscle CSA 66% (Z-score) −1.68
(−5.8–+0.8)
−1 (−6.7–+1.3) 0.301
BMD = bonemineral density, BMC = bonemineral content, CSA = cross-sectional area;
physical activity scores of 13.5, 17 and 20 correspond to 1, 1.5 and 2 h daily activity. b0.05
p-Values are in bold.
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performed with Haploview 4.2. The statistical analysis was performed
on diplotypes due to the relatively small study population.
Statistical analysis
Descriptive data are reported as medians and ranges or as means ±
SD. Association of variables was tested with Pearson or Spearman
correlation, as appropriate. Partial correlation was used to describe the
association after controlling for confounding factor(s). ANOVA was
applied for comparisons between three or more groups, followed by
Bonferroni post hoc test (normally distributed data). Associations be-
tween FGF23 single nucleotide polymorphisms (SNP) and diplotypes,
and biochemical ﬁndings and bone variables were analyzed with
T-test or ANOVA. Part of the associations was further tested with
analysis of covariance (ANCOVA) with relevant covariates. Before mul-
tiple linear regression analyses several variables were log-transformed
to obtain (approximate) normal distribution (for instance for PTH
concentration and calcium intake). Simple regression analysis was
ﬁrst performed to screen potential predictors for site-speciﬁc BMD
with backward method. All calculations were performed using PASW
version 18.0 for Windows. A p-value of less than 0.05 was considered
statistically signiﬁcant and p-values between 0.05 and 0.10 were con-
sidered to indicate trends.
Individual SNPs and FGF23 diplotypes, which combine data on
multiple SNPs, were tested as instrumental variables to estimate causal
effects of serum FGF23 on BMD. Shared covariates (sex, age, height, lean
and fat mass) were chosen for themodel. In addition to S-FGF23, P-PTH
and P-Pi were also tested as modulators (Fig. 1). These analyses were
performed with Stata version 11.0 (with the ivreg2 command).
Results
Clinical ﬁndings, biochemistry and skeletal characteristics
Of the 183 subjects who participated in the present study, 60% (N=
110) were girls and 40% (N= 73) were boys. The participants' age dis-
tribution, pubertal stage, height, fat percentage, total intake of calcium
and vitamin D (combined intakes from diet and supplements), and
physical activity are presented in Table 1. Themedian total intake of cal-
cium and vitamin D were in accordance with ofﬁcial recommendations
[25]. However, individual intakes showed great variation. The partici-
pants were physically active and 80% had normal weight, as described
previously [12]. No difference between the genders was observed in
S-FGF23, S-25(OH)D, P-PTH, P-Pi or U-Pi/U-Crea concentrations, nor in
any of the bone characteristics measured by DXA and pQCT.
After controlling for P-Ca, P-Pi and S-25(OH)D, there was a positive
correlation between S-FGF23 and P-PTH concentrations in pubertal
girls (r = 0.417, p = 0.034), but not in boys (r = 0.284, p = 0.537).
S-FGF23 correlated with U-Ca/U-Crea (r = −0.157, p = 0.049), but
no correlation was observed between S-FGF23 and P-ALP, S-PINP,Fig. 1. Directed acyclic graph for Mendelian randomization analysis of FGF23 genotype on
phenotype and bone outcomes among children aged between 7 and 19 years. Arrows in-
dicate associations, BMD = bone mineral density, LS = lumbar spine and WB= whole
body.S-ICTP, P-Ca and P-Pi, or U-Pi/U-Crea. An inverse association between
S-FGF23 concentrations and fat % Z-score was observed (r =−0.196,
P = 0.031) and it remained after adjusting for calcium intake,
S-25(OH)D and P-PTH levels, and physical activity (r = 0.208 P =
0.020). Physical activity had an effect on S-FGF23 (r = 0.621 P =
0.044) after adjusting for calcium intake, S-25(OH)D, P-PTH and fat %
Z-score. No association between S-FGF23 concentrations and bone
outcomes was observed.
Genetic ﬁndings in FGF23
In the screening of the FGF23 gene we discovered nine variations.
Three of these variations were observed in several individuals and are
summarized in Table 2; these were selected for further analysis. Four
of the nine variations occurred in only one individual: c.723GNA
(P241P) in exon 3 and rs59390594, rs71583766, and c.2681ANG in the
3′UTR. In addition, two subjects of African descent carried variations
rs13312795 and c.2139-2141delTTC, both in the 3′UTR. The subjects
with rare variations did not have hypo- or hyperphosphatemia and
did not differ in other biochemical and skeletal parameters from the
others. The three selected polymorphisms rs3832879 (c.212-37insC),
rs7955866 (c.716CNT, p.T239M) and rs11063112 (c.2185ANT) occurred
in four different haplotype and six different diplotype combinations.
Table 2
Genetic variation in FGF23 in the study population.
db SNP n:o Change Position in gene Genomic position (hg19/human) Variants n (% of 183 screened samples)
AA Aa aa del/ins
rs3832879 c.212-37insC Intron 2 12:4481900-4481899 143 (78) 40 (22)
rs7955866 c.716CNT, p.T239M Exon3 12:4479549 146 (80) 37 (20)
Unknown c.723GNA, p. P241P Exon 3 12:4479542 182 (99) 1 (1)
rs59390594 c.1097 del TTTT 3′UTR 12:4479418 182 (99) 1 (1)
rs13312795 c.1144GNA 3′UTR 12:4479121 181 (99) 2 (1)
rs71583766 c.1754CNG 3′UTR 12:4478511 182 (99) 1 (1)
Unknown c.2139‐2141delTTC 3′UTR 12:4478127-4478129 181 (99) 2 (1)
rs11063112 c.2185ANT 3′UTR 12:4478330 85 (46) 83 (45) 15 (8)
Unknown c.2681ANG 3′UTR 12:4477584 182 (99) 1 (1)
Bolded variants were included in the statistical analyses.
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20.8%), 3 (CCA 10.9%), and 4 (−TT 9.8%), and diplotypeswere Diplotype
1−CA/−CA (32.2%), 2−CA/−TT (16.9%), 3−CA/−CT (29%) 4 CCA/
CCA (14.8%), 5 CCA/−CT (4.9%), and 6 CCA/−TT (2.2%) (Fig. 2).
Associations between FGF23 variations and biochemical or skeletal
characteristics
Variation in rs3832879 (c.212-37insC) genotype correlated with
P-Pi concentration (p = 0.033) (Table 3A). However, no association
were present after controlling for age, gender, pubertal stage and S-
25(OH)D (p = 0.398). We identiﬁed only 716CC and 716CT genotypes
in rs7955866 (c.716CNT, p.T239M). 716CT heterozygotes had signiﬁcant-
ly lower mean P-PTH levels and higher U-Pi/U-Crea levels than 716CC
homozygotes (Table 3A). These differences remained signiﬁcant when
analyzed with ANCOVA, which yielded a p-value of 0.042 for P-PTH
with covariates gender, pubertal stage, S-25(OH)D and calcium intake,
and p = 0.038 for U-Pi/U-Crea with covariates age, gender, pubertal
stage, P-Pi, S-25(OH)D, and calcium intake. No signiﬁcant correlation
between the rs11063112 (c.2185ANT) genotype and other variables
was observed.
When analyzed according to diplotypes (Table 3B) S-FGF23 levels
did not differ between diplotypes in the primary analysis or after adjust-
ment for S-25(OH)D, P-PTH and calcium intake (r = 0.02, p = 0.84).
There was an association between FGF23 diplotype and P-PTHFig. 2. Functional domains of the FGF23 protein, gene structure, and haplotype and diplotype fre
Domain I is the FGF R binding domain and Domain II the Klotho binding domain. In the middle
lotypes and diplotypes in our study population according to the HapMap analysis.concentrations (ANOVA p = 0.032, Table 3B). After controlling for
age, pubertal stage, S-25(OH)D, date of sampling and calcium intake
the difference between FGF23 diplotypes and P-PTH concentrations
remained in girls, but disappeared in boys (ANCOVA; p = 0.037 and
p = 0.636). Of the 16 children with elevated PTH, 94% had the
rs7955866 716CC genotype and 63% the−CA/−CA diplotype while in
the whole study population the corresponding proportions were 78%
and 32%. There was a statistically signiﬁcant difference between the
two groups in the distribution of rs7955866 genotypes (p = 0.018)
and the distribution of diplotypes (p = 0.006). There was a trend to-
ward association between higher S-25(OH)D and FGF23 genetic varia-
tion (P = 0.097) in the whole group which was masked by the gender
interaction: in boys, but not in girls, FGF23 gene variation associated
with S-25(OH)D concentrations (p = 0.032).
In both genders, FGF23 gene variationwas independently associated
with total hip BMD Z-score in a multivariate regression model with
additional variables weight, height, pubertal stage, S-25(OH)D, P-Pi
Z-score and physical activity (p = 0.002; Table 4), but not with other
bone outcomes. The regressionmodel accounted for 14% of the variance
(adjusted R2) in total hip BMD Z-score (Table 4). Among all the inde-
pendent variables weight, height, S-25(OH)D and FGF23 diplotype
were the signiﬁcant determinants of total hip BMD Z-score. No associa-
tion between FGF23 gene variation and other BMD Z-scores, measured
with DXA, or pQCT parameters was noticed in multivariate regression
models.quencies in the study population. Two domains of the FGF23 protein are shown at the top.
we present the genomic structure of the FGF23 gene. The lower panel indicates the hap-
Table 3A
Biochemical ﬁndings and bone variables measured with DXA or pQCT for genotypes of SNPs: rs3832879, rs7955866 and rs11063112. The results are presented as means ± SD.
rs3832879 (c.212-37insC) Intron2 rs7955866 (c.716CNT, p.T239M) Exon3 rs11063112 (c.2185ANT) 3′UTR
−/−
N = 143
−/insC
N = 40
p-Value
T-test,
ANCOVAa
CC
N = 146
CT
N = 37
p-Value
T-test,
ANCOVAb,c
AA
N = 85
AT
N = 83
TT
N = 15
p-Value
ANOVA
S-25(OH)D (nmol/L) 42.0 ± 12.3 42.0 ± 13.4 0.528 41.1 ± 11.9 45.5 ± 14.3 0.158 41.1 ± 12.4 42.2 ± 12.0 45.8 ± 15.6 0.394
P-PTH (ng/L) 46.4 ± 23.0 39.7 ± 17.7 0.302 46.3 ± 23.5 39.7 ± 14.9 0.027, 0.042b 48.1 ± 26.1 42.0 ± 17.3 41.6 ± 20.2 0.181
S-FGF23 (ng/L) 40.0 ± 16.6 38.5 ± 19.6 0.553 40.0 ± 17.4 38.1 ± 17.1 0.534 41.0 ± 17.0 37.4 ± 17.6 45.3 ± 17.2 0.210
P-Ca (mmol/L) 2.32 ± 0.1 2.34 ± 1.9 0.180 2.32 ± 0.1 2.33 ± 0.1 0.748 2.33 ± 0.1 2.33 ± 0.1 2.3 ± 0.9 0.559
P-Pi (mmol/L) 1.42 ± 0.2 1.35 ± 0.2 0.033, 0.398a 1.4 ± 0.2 1.43 ± 0.2 0.393 1.4 ± 0.2 1.4 ± 0.2 1.3 ± 0.3 0.083
U-Ca/U-Crea −0.06 ± 1.0 0.23 ± 0.9 0.429 1.2 ± 0.2 1.2 ± 0.2 0.908 0.12 ± 0.2 0.18 ± 0.1 0.18 ± 0.1 0.949
U-Pi/U-Crea 1.9 ± 1.8 1.9 ± 1.8 0.539 1.7 ± 0.9 2.3 ± 3.1 0.013, 0.038c 1.7 ± 0.9 1.9 ± 2.2 1.8 ± 1.3 0.676
Fat Z −0.4 ± 1.1 −0.3 ± 1.3 0.412 −0.4 ± 1.2 −0.2 ± 1.1 0.855 −0.3 ± 1.1 −0.3 ± 1.1 −0.3 ± 1.4 0.964
LS BMD Z 0.04 ± 0.9 −0.01 ± 1.0 0.390 −0.02 ± 0.9 0.23 ± 0.8 0.187 0.04 ± 0.9 −0.003 ± 0.9 0.11 ± 0.9 0.894
Total hip BMD Z 0.12 ± 0.9 0.013 ± 0.7 0.070, 0.05 ± 0.8 0.25 ± 0.9 0.862 0.2 ± 0.8 0.007 ± 0.8 −0.02 ± 0.9 0.348
WB BMD Z 0.1 ± 0.8 −0,12 ± 0.7 0.675 −0.003 ± 0.8 0.186 ± 0.8 0.743 0.03 ± 0.8 0.01 ± 0.8 0.11 ± 0.8 0.909
BMC 4% Z −0.4 ± 1.1 −0.1 ± 1.2 0.658 −0.3 ± 1.1 −0.3 ± 1.0 0.272 −0.3 ± 1.1 −0.34 ± 1.1 −0.13 ± 1.0 0.785
Trabecular vBMD 4% Z −0.1 ± 1.2 −0.2 ± 1.0 0.084 −0.2 ± 1.2 0.04 ± 1.0 0.267 −0.15 ± 1.1 −0.23 ± 1.2 0.13 ± 1.0 0.505
Total vBMD 4% Z −0.1 ± 1.1 −0.3 ± 1.2 0.870 −0.1 ± 1.2 −0.06 ± 1.1 0.590 −0.05 ± 1.2 −0.23 ± 1.1 0.13 ± 1.1 0.783
SSI 66% Z −0.2 ± 1.2 −0.3 ± 1.4 0.133 −0.23 ± 1.2 −0.24 ± 1.4 0.632 −0.13 ± 1.1 −0.21 ± 1.1 −0.80 ± 1.6 0.169
BMC 66% Z −0.01 ± 1.1 0.2 ± 1.1 0.570 0.003 ± 1.0 0.223 ± 1.2 0.845 −0–04 ± 1.0 0.1 ± 1.1 0.19 ± 1.0 0.785
Cortical vBMD 66% Z −0.5 ± 1.1 −0.5 ± 1.1 0.570 −0.5 ± 11 −0.4 ± 1.3 0.203 −0.5 ± 1.1 −0.54 ± 1.1 −0.02 ± 1.4 0.269
a Covariate; age, gender, pubertal stage, S-25(OH)D.
b Covariates; S-25(OH)D, calcium intake, gender, pubertal stage.
c Covariates; age, gender, pubertal stage, P-Pi, S-25(OH)D, calcium intake. Statistically signiﬁcant differences are in bold (p-Valueb0.05).
128 M. Pekkinen et al. / Bone 71 (2015) 124–130The causality between the genetic variation in FGF23 and bone out-
comes was further investigated by instrument analysis based on the
concept of Mendelian randomization [26]. For possible modulators of
the effect we tested S-FGF23, P-PTH and P-Pi. In the model (Fig. 1), the
S-FGF23 concentration was adjusted for genetic variation, but this
had only a minor effect on S-FGF23 concentration (after adjustment
p = 0.584 between diplotypes). In the next step, bone outcome was
regressed against residuals (unexplained part) of S-FGF23 and adjusted
for shared confounders. No associations were found for diplotypes and
bone outcomes. The strongest association was for total hip BMD (β=
0.6, 95% CI−0.27–1.53, p = 0.169), but for others β varied between
−0.1 and 0.5 and p-values between 0.5 and 0.9. The P-PTH concentra-
tion differed signiﬁcantly between diplotypes (in unadjusted model
p= 0.032) and adjustment for genetic variance strengthened this ﬁnd-
ing (median concentrations 49.6, 46.2, 42.9, and 39.5 ng/L, p for theTable 3B
Biochemical ﬁndings and bone variables measured with DXA or pQCT for each FGF23 diplotyp
Diplotype −CA/−CA
N = 59
−CA/−TT
N = 31
Calcium intake (mg/day) 1480 ± 446.3 1738 ± 547.1
Vitamin D intake (mg/day 10.0 ± 5.2 10.3 ± 5.0
S-25(OH)D (nmol/L) 41.0 ± 11.9 46.8 ± 13.4
P-PTH (ng/L) 51.4 ± 28.2 39.9 ± 15.7
S-FGF23 (ng/L) 41.9 ± 16.9 39.7 ± 18.3
P-Ca (mmol/L) 2.32 ± 0.1 2.32 ± 0.1
P-Pi (mmol/L) 1.43 ± 1.9 1.43 ± 0.2
S-PINP (μg/L) 519 ± 311.3 484.6 ± 317.8
S-ICTP (μg/L) 15.3 ± 5.6 15.1 ± 6.5
U-Ca/U-Crea 0.17 ± 0.1 0.23 ± 0.2
U-Pi/U-Crea 1.8 ± 0.9 2.2 ± 3.4
BMI (Z-score) 0.1 ± 1.1 0.2 ± 1.1
Fat (Z-score) −0.4 ± 1.1 −0.2 ± 1.1
Lumbar spine BMD (Z-score) 0.1 ± 0.1 0.3 ± 0.8
Total hip BMD (Z-score) 0.3 ± 0.9 0.3 ± 0.9
Whole body BMD (Z-score) 0.1 ± 0.8 0.3 ± 0.7
BMC 4% (Z-score) −0.4 ± 1.1 −0.2 ± 0.9
Trabecular vBMD 4% (Z-score) −0.1 ± 1.2 0.0 ± 1.2
Total vBMD 4% (Z-score) 0.0 ± 1.1 −0.1 ± 1.0
SSI 66% (Z-score) −0.1 ± 1.1 −0.1 ± 1.5
BMC 66% (Z-score) −0.1 ± 1.1 0.3 ± 1.3
Cortical vBMD 66% (Z-score) −0.5 ± 1.1 −0.2 ± 1.3
Muscle CSA 66% (Z-score) −1.5.0 ± 1.1 −1.9 ± 1.6difference 0.019), but the unexplained part of PTH did not associate
with bone outcomes. Similarly, in a crude model, P-Pi did not differ
between diplotypes (p = 0.208), but the genetic variants of FGF23
explained some of the variance as some differences emerged after
adjustment (p = 0.084). Again residuals of P-Pi did not associate with
bone outcomes. Thus, genetic variance in FGF23 was considered a
weak instrument as it induced rather small variation in S-FGF23,
P-PTH and P-Pi (F statistic less than 10; but higher for P-PTH and P-Pi
than for S-FGF23) and ultimately no causal effects on skeletal parame-
ters could be seen.
Discussion
The detrimental effects of abnormal serum phosphate concentra-
tions on bone mineralization and cardiovascular morbidity ande. Results are presented as means ± SD. b0.05 p-Values are in bold.
−CA/−CT
N = 53
CCA/CCA, CCA/−CT,
CCA/−TT
N = 40
p-Value ANOVA
1391 ± 487.8 1619.8 ± 776.7 0.063
10.8 ± 5.6 10.3 ± 5.6 0.918
40.0 ± 11.3 42.0 ± 13.4 0.097
44.6 ± 18.9 39.7 ± 17.7 0.032
37.9 ± 15.4 38.5 ± 19.6 0.658
2.32 ± 0.1 2.34 ± 0.1 0.605
1.42 ± 0.2 1.35 ± 0.2 0.203
526.4 ± 309.8 369.1 ± 261.3 0.063
15.4 ± 5.2 12.6 ± 5.1 0.068
0.17 ± 0.2 0.19 ± 0.1 0.222
1.7 ± 0.8 1.5 ± 0.8 0.372
−0.1 ± 1.1 0.1 ± 1.2 0.695
−0.4 ± 1.1 −0.3 ± 1.3 0.753
−0.2 ± 0.9 −0.1 ± 0.1 0.182
−0.1 ± 0.8 0.1 ± 0.7 0.052
−0.1 ± 0.8 −0.1 ± 0.8 0.138
−0.4 ± 1.1 −0.1 ± 1.2 0.531
−0.3 ± 1.2 −0.2 ± 1.0 0.735
−0.1 ± 1.0 −0.3 ± 1.2 0.672
−0.4 ± 1.1 −0.3 ± 1.4 0.518
−0.1 ± 1.0 0.2 ± 1.1 0.465
−0.6 ± 1.1 −0.5 ± 1.1 0.462
−1.9 ± 1.5 −1.5 ± 1.3 0.301
Table 4
Linear regression analysis for determinants of total hip BMD Z-scores.
Total hip BMD (Z-score)
Adjusted r2 β p
(N = 142)
Regression model 0.142 0.002
Height (cm) −0.552 b0.001
Weight (kg) 0.552 b0.001
S-25-OHD (nmol/L) 0.141 0.048
FGF23 diplotype −0.136 0.046
Exercise (physical activity score) 0.065 0.374
PPi-Z score 0.048 0.558
Pubertal stage −0.100 0.920
β values are standardized. Determinants with bold p-value are included in the model.
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have the complex control mechanisms of phosphate metabolism
begun to unravel. The discovery of the osteoblast/osteocyte-derived
FGF23 as a phosphaturic agent and a regulator of vitamin Dmetabolism
has clariﬁed the hormonal cross-talk between bone tissue, kidneys
and parathyroid glands. Still many aspects of phosphate homeostasis
and the underlying cellular pathways remain inadequately deﬁned.
The approach of this study was to evaluate the impact of genetic
variation in the FGF23 gene on phosphate homeostasis and bone out-
comes in healthy children and adolescents. Factors such as demo-
graphics, dietary intake, fasting status and time of day at sampling,
cardiovascular risk factors and kidney function only account for approx-
imately 12% of the variation in serum phosphate levels [27]. Thus other
factors, such as genetic variability, are likely to inﬂuence phosphate
homeostasis.
Our hypothesis was that more subtle changes in FGF23 function
could cause measureable alterations in phosphate metabolism and
bone health. Upon sequencing of the FGF23 gene we discovered nine
single nucleotide changes: seven SNPs, one deletion and one insertion.
Three of these were common: rs3832879, rs7955866 and rs11063112.
In two of the SNPs, rs3832879 and rs7955866, the variation was dichot-
omous; only AA homozygotes and Aa heterozygotes were present.
Instrument analysis did not show a link between FGF23 genetic varia-
tion and S-FGF23 concentration. One reason could be the lack of aa ho-
mozygotes in our data and another reason might be that in this study
we measured only total intact S-FGF23, not c-terminal FGF23. Rendina
et al. [10] have shown association between rs7955866 (FGF23716T)
and calcium nephrolithiasis with renal phosphate leak and lower P-Pi
concentrations. In our data, the 716CT genotype associated with lower
P-Pi and higher U-Pi/U-Crea levels, which is in line with earlier results
[10]. We show for the ﬁrst time an association between genetic
variation in FGF23 (716CT genotypes or FGF23 diplotypes) and P-PTH
concentrations in the general population. Genetic variation in terms of
diplotypes reinforced variation in PTH (a secondary outcome) and
covered some of the variation in P-Pi, but not in S-FGF23. This implies
that the genetic variation in FGF23 is not functional or that other
compensating mechanisms exist.
The only genome-wide association study focusing on genetic
variants inﬂuencing serum phosphate concentrations, established
statistically signiﬁcant associations for ﬁve different genomic regions.
The implicated regions contained genes encoding tissue-nonspeciﬁc
alkaline phosphatase (ALPL), the calcium-sensing receptor (CASR), a
regulator of G-protein signaling (RGS14), a kidney-speciﬁc sodium-
phosphate transporter (SLC34A1), phosphodiesterase 7B (PDE7B),
ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) and
FGF6. Noticeably, the gene encoding the only FGF known to affect phos-
phate homeostasis, FGF23, is located only 133 kb upstream from the
associating SNP in FGF6 [28,29]. This study implicated many different
genes known to affect calcium and phosphate uptake, metabolism
and secretion, but did not look into clinical phenotypes linked to the
genetic changes. Hitherto only signiﬁcant clinical phenotypes, such ashypophosphatemic rickets, ﬁbrous dysplasia in McCune Albright-
syndrome and Jansen metaphyseal condrodysplasia, have been
coupled to mutations in genes affecting the transcription, function and
metabolism of FGF23 and associated pathways. Inactivating mutations
in FGF23, PHEX, DMP1, ENPP1, and ANK-1 and activating mutations in
FGFR1, GNAS, FGF2-HMW, and PTH/PTHr receptor are known to cause a
decrease in mineralization of the extracellular matrix (osteomalacia),
high FGF23 concentrations, hypophosphatemia and low 1,25(OH)2D
levels [30].
The synthesis of FGF23 by osteoblasts and osteocytes is induced by
high S-1,25(OH)2D and P-Pi concentrations. We only measured
25(OH)D concentrations as part of this study, but in the future assess-
ments of 1,25(OH)2D may be warranted. P-Ca and P-PTH levels affect
the release of phosphate from bone tissue, but do not directly control
the production of FGF23. In our study, 9% of the subjects had elevated
P-PTH concentrations (N74 ng/L) and all had normal P-Ca levels. In ad-
dition, results demonstrated association between rs3832873 (c.212-
37insC) SNP in the FGF23 gene and P-Pi concentrations. High P-Pi levels,
as in chronic kidney failure, cause soft tissue calciﬁcation and related
vascular diseases [6]. An elevated risk for vascular calciﬁcation andmor-
bidity can also be seen in otherwise healthy individuals with elevated
circulating phosphate levels [31]. Our study focused on phosphate
metabolism and bone parameters, and due to the young age of our sub-
jects no screening for vascular disease was performed. However, as our
results indicate that one polymorphism (rs3832879, c.212-37insC) is
linked to elevated P-Pi levels even in children, this polymorphism
could possibly explain some of the variation in phosphate levels in the
general population. Interestingly, the FGF23 variation associated with
total hip BMD Z-scores but not with other skeletal parameters. It can
be hypothesized that since this skeletal site reﬂects effects of bone load-
ing, it would be impacted more than other skeletal sites by variation in
an osteocyte-speciﬁc factor. Unfortunately our data does not allow for
more detailed assessment of this association.
Our material is limited, as we assessed only 183 children. The Inter-
national Society for Clinical Densitometry recommends that in children
total body less head BMD rather than total body BMD values are used
[32]. However, no normative data were available to calculate total
body less head Z-score values and we therefore used total body BMD
values. It is unlikely that this impacted our ﬁndings. We measured the
P-Pi levels once, albeit at the same time of day and after an over-night
fasting for all subjects. P-Pi levels normally vary from day to day and
during the course of a day, but the most reliable results are achieved
in the morning after fasting [27]. The known tendency for variation
may affect the validity of our ﬁndings. We were unable to evaluate
phosphorus intake with a more speciﬁc dietary inquire. In future stud-
ies, it would be important to obtain information on phosphorus intake,
which is an important variable and providesmore information on phos-
phorus metabolism.Conclusion
This is the ﬁrst study exploring associations between FGF23
polymorphisms and clinical phenotypes, and we succeeded in
showing a weak but statistically signiﬁcant association between
rs7955866 (c.716CNT, p.T239M) genotype and P-PTH concentration
and U-Pi/U-Crea in healthy school children. In addition, we found an
association between FGF23 diplotype and total hip BMD Z-scores, but
not with other skeletal parameters. We observed a genetic variant
that inﬂuences circulating PTH and phosphate without affecting
serum FGF23 concentration. Future studies are needed to conﬁrm our
ﬁndings in a larger cohort and to elucidate the impact of other genes im-
plicated in phosphate homeostasis [27] on bone density parameters and
cardiovascular morbidity as to better clarify the link between gene
polymorphisms and diseases secondary to variations in phosphate
regulation.
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